Alcolase secures £1.3m to tackle alcohol intolerance in East Asia
BevTech startup Alcolase raises £1.3m for enzyme technology addressing alcohol intolerance in 540M people, showcasing biotech innovation in beverage consumption and health.
Why does this matter?
BevTech startup Alcolase raises £1.3m for enzyme technology addressing alcohol intolerance in 540M people, showcasing biotech innovation in beverage consumption and health.
Highlights
Danish biotech startup Alcolase has locked in £1.3m of funding to create an enzyme-based treatment for ALDH2 deficiency – an alcoholic intolerance condition that affects around 540 million people in East Asia. The post Alcolase secures £1.3m to tackle alcohol intolerance in East Asia appeared first on The Drinks Business.
Source: The Drinks Business
